Targeted therapy for NSCLC with driver mutations

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Levy MA, Lovly CM and Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res 2012;22:2101-8
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes—the achilles heal of cancer. Science 2002;297:63-4
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutations-positive non-small cell lung cancer (EURTAC) a multicenter, open-label, randomized phase 3 trial. Results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• Yang JC, Schuler MH, Yamamoto M, et al. LUX-Lung 3: A Randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for pantients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO Annual Meeting, Oral Abstract Session, Lung Cancer - Non-small Cell Metastatic. J Clin Oncol 2012;30(Suppl):abstract LBA7500
   Google Scholar
• Govindan R, Ding L, Griffith M, et al. Genomic landscape non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34
   PubMed Web of Science ®Google Scholar
• Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplex genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(Suppl):abstract CRA7506
   Google Scholar
• Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8000
   Google Scholar
• Doebele RC, Vaishnavi A, Capelletti M, et al. NTRK1 gene fusions as a novel oncogene target in lung cancer. ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8023
   Google Scholar
• Wang R, Hu H. Pan Y et l. RET fusions define unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-9
   PubMed Web of Science ®Google Scholar
• Davies K, Le A, Theodoro M, et al. Identifying and targeting ROS1 gene fusions in non-small-cell lung cancer. Clin Cancer Res 2012;18:4570-9
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Chiarle R, Gong J, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003;101:1919-27
   PubMed Web of Science ®Google Scholar
• Solmon B, Varella-Garcia M, et Camidge DR. ALK gene rearrangements, a new therapeutic target in molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-4
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK- rearranged lung adenocarcinoma in western population. Clin Cancer Res 2009;15:5216-23
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from Phase 1 study. Lancet Oncol 2012;13:1011-19
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Doebele RC, Aisner DL, Le AT, et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. ASCO meeting 2012. J Clin Oncol 2012;30(Suppl):abstract 7504
   Google Scholar
• Shaw AT, Mehra R, Kim DW, et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8010
   Google Scholar
• Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013;3:430-43
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8031
   Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 2013;14:590-8
   PubMed Web of Science ®Google Scholar
• Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptor like molecule. Mol Cell Biol 1986;6:3000-4
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70
   PubMed Web of Science ®Google Scholar
• Yashuda H, de Figueiredo-Pontes LL, Kobayashi S, et al. Preclinical rationale for use of the clinically available miltitarget tyrosine kinase inhibitor crizotinib in ROS1-translocted lung cancer. J Thorac Oncol 2012;7:1086-90
   PubMedGoogle Scholar
• Ou SHI, Bang YJ, Camidge DR, et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8032
   Google Scholar
• Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16:5936-41
   PubMed Web of Science ®Google Scholar
• Wells SA, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009;15:7119-23
   PubMed Web of Science ®Google Scholar
• Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non–small-cell lung cancer. J Clin Oncol 2012;30:4352-9
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusion in lung adenocarcinoma. Nat Med 2012;18:375-7
   PubMed Web of Science ®Google Scholar
• Li F, Feng Y, Fang R, et al. Identification of RET gene fusion by exon array analyses in “pannegative” lung cancer from never smokers. Cell Res 2012;22:928-31
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized double-blind phase III trial. J Clin Oncol 2012;30:134-41
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Lung adenocarcinomas response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Dicov 2013; doi:10.1158/2159-8290
   Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
   PubMed Web of Science ®Google Scholar
• Ichimura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human non small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87:1063-9
   PubMedGoogle Scholar
• Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-1674a
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-6
   PubMed Web of Science ®Google Scholar
• Ma P, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012;30:3287-96
   PubMed Web of Science ®Google Scholar
• Mok TS, Park K, Geater SL, et al. A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab a humanized hepatocyte growth factor inhibitory MAB in combination with gefitinib versus gefitinib in Asian patients with lung adenocarcinoma. Ann Oncol 2012;23:abstract 1198P
   Google Scholar
• Surati M, Patel P, Peterson A, et al. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011;11:1655-62
   PubMed Web of Science ®Google Scholar
• Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, et al. Distinct set of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47
   PubMed Web of Science ®Google Scholar
• Naoki K, Chen TH, Richards WG, et al. Missense mutations of BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Sasaki H, Kawano O, Endo K, et al. Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 2006;133:203-6
   PubMed Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinoma harboring BRAF mutations. J Clin Oncol 2011;29:2046-51
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-9
   PubMed Web of Science ®Google Scholar
• Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the miogeno-activated protein kinase pathway in lung cancer models. Cancer Res 2007;67:4933-9
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Gautschi O, Chantal P, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-4
   PubMed Web of Science ®Google Scholar
• Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012;72:779-89
   PubMed Web of Science ®Google Scholar
• Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. ASCO meeting 2013. J Clin Oncol 2013;31(Suppl):abstract 8009
   Google Scholar
• Hirsch FR, Franklin WA, Veve R, et al. Her2/neu expression in malignant lung tumors. Semin Oncol 2002;29:51-8
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shark S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controller trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-18
   PubMed Web of Science ®Google Scholar
• Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010;5:1922-32
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Cho YG, Sacconi A, et al. p95HER2 truncated form in resected non-small cell lung cancer. J Thorac Oncol 2012;7:520-7
   PubMed Web of Science ®Google Scholar
• Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations tumours. Nature 2004;431:525-6
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-6
   PubMed Web of Science ®Google Scholar
• Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations and molecular spectrum of ERBB2(HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-19
   PubMed Web of Science ®Google Scholar
• Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011;74:139-44
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354:2619-21
   PubMed Web of Science ®Google Scholar
• De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-7
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Carter C, Giaccone G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 2010;28:e507-10
   PubMed Web of Science ®Google Scholar
• Kris M, Goldberg Z, Janne PA, et al. Dacomitinib (PF-00299804), an irreversible pan-HER2 tyrosine kinase inhibitor (TKI), for first line treatment of EGFR-mutant or HER2-mutant or-amplified lung cancers. Ann Oncol 2012;23:ix401-2
   Google Scholar
• Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors a HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Campbell SL, Khosravi-Far R, Rossmann KL, et al. Increasing complexity of RAS signaling. Oncogene 1998;17:1395-413
   PubMed Web of Science ®Google Scholar
• Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; [Epub ahead of print]
   Google Scholar
• Camps C, Jantus-Lewintre E, Cabrera A, et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011;72:365-9
   PubMed Web of Science ®Google Scholar
• Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010;69:110-15
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:0057-61
   Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19
   PubMed Web of Science ®Google Scholar
• Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47
   PubMed Web of Science ®Google Scholar
• Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-73
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25
   PubMed Web of Science ®Google Scholar
• Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008;111:4797-808
   PubMed Web of Science ®Google Scholar
• Ford CE, Lau SK, Zhu CQ, et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 2007;96:808-14
   PubMed Web of Science ®Google Scholar
• Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21
   PubMed Web of Science ®Google Scholar
• Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54:209-15
   PubMed Web of Science ®Google Scholar
• Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012;11:485-91
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6
   PubMed Web of Science ®Google Scholar
• Mason I. Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat Rev Neurosci 2007;8:583-96
   PubMed Web of Science ®Google Scholar
• Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010;8:1439-52
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93
   PubMed Web of Science ®Google Scholar
• Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013;31:731-17
   PubMed Web of Science ®Google Scholar
• Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012;7:1775-80
   PubMed Web of Science ®Google Scholar